Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News ME Therapeutics Holdings Inc C.METX

Alternate Symbol(s):  METXF

Healthcare Biotechnology
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099... see more

Recent & Breaking News (CSE:METX)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Business Wire October 16, 2025

ME Therapeutics Added to CSE25 Index

Business Wire October 10, 2025

Canadian Investment Regulatory Organization Trade Resumption - METX

Canada NewsWire September 26, 2025

ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs

Business Wire September 26, 2025

Canadian Investment Regulatory Organization Trading Halt - METX

Canada NewsWire September 26, 2025

ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease

Business Wire May 21, 2025

ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE

Newsfile March 3, 2025

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Newsfile January 14, 2025

ME Therapeutics Holdings Inc. Appoints Chief Business Officer

Newsfile October 25, 2024

ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

Newsfile October 22, 2024

ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

Newsfile September 18, 2024

ME Therapeutics to collaborate with NanoVation Therapeutics

Jocelyn Aspa July 8, 2024

ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

Newsfile July 8, 2024

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile June 13, 2024

ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

Newsfile May 29, 2024

ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

Newsfile May 17, 2024

ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

Newsfile April 15, 2024

ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

Newsfile March 26, 2024

ME Therapeutics Announces Closing of Non-Brokered Private Placement

Newsfile March 6, 2024

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

Newsfile February 27, 2024